Allison Zulli
About Allison Zulli
Allison Zulli is a Senior Scientist at Venatorx Pharmaceuticals Inc., where she has worked since 2014. Her research focuses on antimicrobial resistance mechanisms in Gram-negative bacteria and includes contributions to the development of β-lactamase inhibitors.
Work at Venatorx Pharmaceuticals
Allison Zulli has been employed at Venatorx Pharmaceuticals Inc. as a Senior Scientist since 2014. Over her tenure of 10 years, she has worked in Malvern, Pennsylvania, contributing to the company's research and development efforts. Her role involves significant engagement in projects aimed at combating antimicrobial resistance and developing innovative treatments for bacterial infections.
Research Focus and Contributions
Zulli's research primarily centers on antimicrobial resistance mechanisms in Gram-negative bacteria. She has participated in studies that address the challenges of outpatient treatment for multi-drug-resistant bacterial infections. Her work aims to enhance understanding and develop solutions to combat these pressing health issues.
Publications and Discoveries
Allison Zulli co-authored a publication detailing the discovery of VNRX-7145, an orally bioavailable β-lactamase inhibitor. This work contributes to the broader field of antibiotic resistance and showcases her involvement in significant scientific advancements within the pharmaceutical industry.
Development of β-lactamase Inhibitors
Zulli has contributed to the development of a boronic acid-containing β-lactamase inhibitor. This work is part of her ongoing efforts to create effective treatments against resistant bacterial strains, highlighting her role in advancing therapeutic options in the field of infectious diseases.